Aileron Therapeutics, Inc. (ALRN) News

Aileron Therapeutics, Inc. (ALRN): $4.74

0.26 (-5.20%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add ALRN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#174 of 362

in industry

Filter ALRN News Items

ALRN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ALRN News From Around the Web

Below are the latest news stories about AILERON THERAPEUTICS INC that investors may wish to consider to help them evaluate ALRN as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today!

William White on InvestorPlace | December 15, 2023

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. Immediately following the acquisition of Lung Tx, Aileron entered into a definitive agreement for the sale of shares of Aileron's Series X non-voting convertible preferred stock

Yahoo | October 31, 2023

Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | April 4, 2023

Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | March 14, 2023

Cancer drugmaker down to 3 employees after trial failure

A cancer firm has gone from a paltry nine employees to an even scanter three after a chemoprotective drug failed in clinical trials.

Yahoo | February 22, 2023

Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall

Aileron Therapeutics (NASDAQ: ALRN) announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast cancer showed severe neutropenia (Grade 4) and alopecia (hair loss). The primary endpoint of the Phase 1b open-label trial was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, or "TAC" chemotherapy, was the duration and incidence of severe neutropenia

Yahoo | February 21, 2023

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint of the Phase 1b open-label trial, which was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, a

Yahoo | February 21, 2023

What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock

Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 29, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!